Novel Cruzain Inhibitors for the Treatment of Chagas' Disease

Chemical Biology and Drug Design

Volumn 80, Issue 3, 2012, Pages 398-405

  Rogers, Kathleen E ^a   Keränen, Henrik ^b   Durrant, Jacob D ^a   Ratnam, Joseline ^c   Doak, Allison ^c   Arkin, Michelle R ^c   Mccammon, J Andrew ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chagas' disease; Computer aided drug discovery; Cruzain; Cruzipain; Cysteine protease inhibitor; Trypanosoma cruzi

Indexed keywords

CRUZIPAIN; CYSTEINE PROTEINASE INHIBITOR; NSC 227186; NSC 260594; NSC 67436; UNCLASSIFIED DRUG;

ARTICLE; CHAGAS DISEASE; CRYSTAL STRUCTURE; DISEASE COURSE; DRUG SCREENING; DRUG TARGETING; IC 50; MOLECULAR DYNAMICS; PRIORITY JOURNAL; TRYPANOSOMA; TRYPANOSOMA CRUZI; VALIDATION STUDY;

CHAGAS DISEASE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTOZOAN PROTEINS; SMALL MOLECULE LIBRARIES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

PROTOZOA; TRYPANOSOMA CRUZI;

EID: 84864117405     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01416.x     Document Type: Article

References (51)

1. Rassi A., Rassi A., Marin-Neto J.A. (2010) Chagas disease. Lancet;375:1388-1402.
2. Shulman I.A., Appleman M.D., Saxena S., Hiti A.L., Kirchhoff L.V. (1997) Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion;37:727-731.
3. Higuchi M.de.L., Benvenuti L.A., Martins Reis M., Metzger M. (2003) Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res;60:96-107.
4. Tanowitz H.B., Kirchhoff L.V., Simon D., Morris S.A., Weiss L.M., Wittner M. (1992) Chagas' disease. Clin Microbiol Rev;5:400-419.
5. Prata A. (2001) Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis;1:92-100.
6. Coura J.R., de Castro S.L. (2002) A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz;97:3-24.
7. Castro J.A., de Mecca M.M., Bartel L.C. (2006) Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol;25:471-479.
8. Jackson Y., Alirol E., Getaz L., Wolff H., Combescure C., Chappuis F. (2010) Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis;51:e69-e75.
9. Quijano-Hernandez I., Dumonteil E. (2011) Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin;7:1184-1191.
10. Tomas A.M., Miles M.A., Kelly J.M. (1997) Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis. Eur J Biochem;244:596-603.
11. Doyle P.S., Zhou Y.M., Hsieh I., Greenbaum D.C., McKerrow J.H., Engel J.C. (2011) The Trypanosoma cruzi protease cruzain mediates immune evasion. PLoS Pathog;7:e1002139.
12. McKerrow J.H., Rosenthal P.J., Swenerton R., Doyle P. (2008) Development of protease inhibitors for protozoan infections. Curr Opin Infect Dis;21:668-672.
13. Brinen L.S., Hansell E., Cheng J., Roush W.R., McKerrow J.H., Fletterick R.J. (2000) A target within the target: probing cruzain's P1′ site to define structural determinants for the Chagas' disease protease. Structure;8:831-840.
14. Kerr I.D., Lee J.H., Farady C.J., Marion R., Rickert M., Sajid M., Pandey K.C., Caffrey C.R., Legac J., Hansell E., McKerrow J.H., Craik C.S., Rosenthal P.J., Brinen L.S. (2009) Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem;284:25697-25703.
15. Bryant C., Kerr I.D., Debnath M., Ang K.K., Ratnam J., Ferreira R.S., Jaishankar P., Zhao D., Arkin M.R., McKerrow J.H., Brinen L.S., Renslo A.R. (2009) Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett;19:6218-6221.
16. Sajid M., Robertson S.A., Brinen L.S., McKerrow J.H. (2011) Cruzain : the path from target validation to the clinic. Adv Exp Med Biol;712:100-115.
17. Choe Y., Brinen L.S., Price M.S., Engel J.C., Lange M., Grisostomi C., Weston S.G., Pallai P.V., Cheng H., Hardy L.W., Hartsough D.S., McMakin M., Tilton R.F., Baldino C.M., Craik C.S. (2005) Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorg Med Chem;13:2141-2156.
18. Huang L., Brinen L.S., Ellman J.A. (2003) Crystal structures of reversible ketone-based inhibitors of the cysteine protease cruzain. Bioorg Med Chem;11:21-29.
19. Huang L., Lee A., Ellman J.A. (2002) Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J Med Chem;45:676-684.
20. Dimasi J.A. (2001) Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther;69:297-307.
21. Dolinsky T.J., Czodrowski P., Li H., Nielsen J.E., Jensen J.H., Klebe G., Baker N.A. (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res;35:W522-W525.
22. Dolinsky T.J., Nielsen J.E., McCammon J.A., Baker N.A. (2004) PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res;32:W665-W667.
23. Duschak V.G., Couto A.S. (2009) Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Curr Med Chem;16:3174-3202.
24. Krammer A., Kirchhoff P.D., Jiang X., Venkatachalam C.M., Waldman M. (2005) LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model;23:395-407.
25. Gehlhaar D.K., Verkhivker G.M., Rejto P.A., Sherman C.J., Fogel D.B., Fogel L.J., Freer S.T. (1995) Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol;2:317-324.
26. Muegge I., Martin Y.C. (1999) A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J Med Chem;42:791-804.
27. Muegge I. (2006) PMF scoring revisited. J Med Chem;49:5895-5902.
28. Durrant J.D., Keranen H., Wilson B.A., McCammon J.A. (2010) Computational identification of uncharacterized cruzain binding sites. PLoS Negl Trop Dis;4:e676.
29. Christen M., Hunenberger P.H., Bakowies D., Baron R., Burgi R., Geerke D.P., Heinz T.N., Kastenholz M.A., Krautler V., Oostenbrink C., Peter C., Trzesniak D., van Gunsteren W.F. (2005) The GROMOS software for biomolecular simulation: GROMOS05. J Comput Chem;26:1719-1751.
30. Ferreira R.S., Bryant C., Ang K.K., McKerrow J.H., Shoichet B.K., Renslo A.R. (2009) Divergent modes of enzyme inhibition in a homologous structure-activity series. J Med Chem;52:5005-5008.
31. Feng B.Y., Simeonov A., Jadhav A., Babaoglu K., Inglese J., Shoichet B.K., Austin C.P. (2007) A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem;50:2385-2390.
32. McGovern S.L., Helfand B.T., Feng B., Shoichet B.K. (2003) A specific mechanism of nonspecific inhibition. J Med Chem;46:4265-4272.
33. Sherman W., Day T., Jacobson M.P., Friesner R.A., Farid R. (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem;49:534-553.
34. Sherman W., Beard H.S., Farid R. (2006) Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des;67:83-84.
35. Chagas C. (1909) New human trypanosomiasis. Morphology and life cycle of Schyzotrypanum cruzi, the cause of a new human disease. Mem Inst Oswaldo Cruz;1:159-218.
36. Chagas C. (1911) A new human disease. Summary of etiological and clinical studies. Mem Inst Oswaldo Cruz;3:219-275.
37. Wilkinson S.R., Taylor M.C., Horn D., Kelly J.M., Cheeseman I. (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA;105:5022-5027.
38. Lauria-Pires L., Braga M.S., Vexenat A.C., Nitz N., Simoes-Barbosa A., Tinoco D.L., Teixeira A.R. (2000) Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg;63:111-118.
39. Schames J.R., Henchman R.H., Siegel J.S., Sotriffer C.A., Ni H., McCammon J.A. (2004) Discovery of a novel binding trench in HIV integrase. J Med Chem;47:1879-1881.
40. Lin J.H., Perryman A.L., Schames J.R., McCammon J.A. (2002) Computational drug design accommodating receptor flexibility: the relaxed complex scheme. J Am Chem Soc;124:5632-5633.
41. Amaro R.E., Schnaufer A., Interthal H., Hol W., Stuart K.D., McCammon J.A. (2008) Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc Nat Acad Sci;105:17278-17283.
42. Durrant J.D., Hall L., Swift R.V., Landon M., Schnaufer A., Amaro R.E. (2010) Novel naphthalene-based inhibitors of Trypanosoma brucei RNA editing ligase 1. PLoS Negl Trop Dis;4(8): e803.
43. Durrant J.D., Cao R., Gorfe A.A., Zhu W., Li J., Sankovsky A., Oldfield E., McCammon J.A. (2011) Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. Chem Biol Drug Des;78:323-332.
44. Durrant J.D., Urbaniak M.D., Ferguson M.A., McCammon J.A. (2010) Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4′-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness. J Med Chem;53:5025-5032.
45. Wang Y., Hess T.N., Jones V., Zhou J.Z., McNeil M.R., Andrew McCammon J. (2011) Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-l-lyxo-4-hexulose reductase (RmlD) identified by virtual screening. Bioorg Med Chem Lett;21:7064-7067.
46. Morris G.M., Huey R., Olson A.J. (2008) Using AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics;Chapter 8: Unit 8 14.
47. Wang R., Wang S. (2001) How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci;41:1422-1426.
48. Bar-Haim S., Aharon A., Ben-Moshe T., Marantz Y., Senderowitz H. (2009) SeleX-CS: a new consensus scoring algorithm for hit discovery and lead optimization. J Chem Inf Model;49:623-633.
49. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res;28:235-242.
50. Gillmor S.A., Craik C.S., Fletterick R.J. (1997) Structural determinants of specificity in the cysteine protease cruzain. Protein Sci;6:1603-1611.
51. Mott B.T., Ferreira R.S., Simeonov A., Jadhav A., Ang K.K., Leister W., Shen M., Silveira J.T., Doyle P.S., Arkin M.R., McKerrow J.H., Inglese J., Austin C.P., Thomas C.J., Shoichet B.K., Maloney D.J. (2010) Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. J Med Chem;53:52-60.